Axelsen, Trine V.
Olesen, Claus
Khan, Danish
Mohammadi, Ali
Bouzinova, Elena V.
Nielsen, Christine J. F.
Mele, Marco
Hauerslev, Katrine R.
Pedersen, Helene L.
Balling, Eva
Vahl, Pernille
Tramm, Trine
Christiansen, Peer M.
Boedtkjer, Ebbe http://orcid.org/0000-0002-5078-9279
Funding for this research was provided by:
Novo Nordisk Fonden (NNF15OC0015690, NNF18SA0035216)
Innovationsfonden (0160-00007B)
Det Frie Forskningsråd (2034-00185B)
Article History
Received: 20 September 2023
Revised: 9 January 2024
Accepted: 17 January 2024
First Online: 3 February 2024
Competing interests
: EB is inventor on an issued patent (EP 3271402) covering NBCn1 inhibitory antibodies in cancer.
: The sampling of human tissue was performed with written informed consent and approved by the Mid-Jutland Regional Committee on Health Research Ethics (M-20100288) and the Danish Data Protection Agency (1-16-02-191-16). The study was performed in accordance with the Declaration of Helsinki.